Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in autoimmune skin treatments [1][2]. Group 1: Product Development and Market Position - The active ingredient of ZORYVE® is Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the production of pro-inflammatory mediators [1]. - The cream is part of a collaboration with Arcutis Biotherapeutics, Inc., granting Huadong Medicine exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [1]. - The application targets a significant unmet need in the market, particularly for children aged 2 to 5, where treatment options are currently limited to traditional topical corticosteroids and calcineurin inhibitors [2]. Group 2: Market Demand and Clinical Need - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical demand [2]. - The prevalence of atopic dermatitis in children aged 1 to 7 is reported at 12.94%, highlighting the urgent need for safe and effective treatment options for this age group [2]. - The acceptance of the 0.05% cream application is expected to provide new treatment options for pediatric patients, establishing a differentiated market barrier and first-mover advantage for Huadong Medicine in a competitive landscape [2]. Group 3: Broader Product Portfolio - Huadong Medicine has developed a differentiated product pipeline that includes various concentrations of Roflumilast cream, with higher concentrations (0.15% and 0.3%) also having received regulatory acceptance for treating older patients with atopic dermatitis and psoriasis [3]. - Additionally, a foam formulation of Roflumilast (ZORYVE®) 0.3% for seborrheic dermatitis in patients aged 9 and above is currently undergoing Phase III clinical trials [3].

每经AI快讯，2月3日，华东医药（000963）(000963.SZ)公告称，全资子公司中美华东收到国家药品监 督管理局签发的《受理通知书》，罗氟司特乳膏(ZORYVE)0.05%上市许可申请获得受理，申报适应症 为适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。该药物是中美华东与美国Arcutis Biotherapeutics,Inc.合作引进的创新皮肤外用制剂产品，中美华东拥有在大中华区及东南亚的独家权 益。罗氟司特乳膏0.05%相比传统治疗手段有安全性优势，且可用于所有部位，每日一次给药，提高治 疗依从性。该产品研发进程中的重要里程碑，将提升公司在自免皮肤治疗领域的核心竞争力。但药品审 评审批时间、审批结果及未来市场竞争形势存在不确定性。 ...